Immunotherapy in gastrointestinal malignancies

Book Section

Recent reports of efficacy of immune therapies in solid tumors other than melanoma and renal cell carcinoma have raised enthusiasm for testing immunotherapy in gastrointestinal (GI) malignancies. Strategies under development include antibodies and related molecules that mediate cellular cytotoxicity, vaccines intended to activate tumor-specific T cell and antibody responses, adoptive transfer of natural killer (NK) cells, tumor infiltrating lymphocytes, and chimeric antigen receptor T cells, and immunomodulatory drugs such as checkpoint blocking antibodies. Thus far, benefit has been modest although insights from these studies have provided new directions for testing. We will review the current status of the various immunotherapy approaches undergoing testing in GI malignancies.

Full Text

Duke Authors

Cited Authors

  • Morse, MA

Published Date

  • August 30, 2016

Book Title


Start / End Page

  • 27 - 69

International Standard Book Number 13 (ISBN-13)

  • 9789814651875

Digital Object Identifier (DOI)

  • 10.1142/9789814651875_0002

Citation Source

  • Scopus